Cardiology23 Jul 2026
Why cardiac amyloidosis diagnoses are surging and what it means for GPsRead article
Cardiology23 Jul 2026
Lipids are optimized, but CAD persists. Is inflammation the real enemy?Read article
The Life Science Feed
Deep dives with clinicians, researchers, and industry leaders.
All episodes
Men Face Later Cancer Diagnoses Across 20 Types
Men are more likely to receive a later-stage cancer diagnosis across 20 different cancer types, leading to worse prognoses and treatment outcomes.
Sitting for Long Stretches Linked to Higher Cancer Mortality Risk
Extended sedentary time increases the risk of death from cancer, particularly for specific cancer types, independent of physical activity levels.
FDA Expands Chemo-Free Bladder Cancer Combo for Curative Setting
The FDA broadened approval for a chemotherapy-free combination in bladder cancer, offering a new option for patients ineligible for cisplatin.
Chronic Hepatitis Delta Virus: Why direct viral targeting matters now
The FDA has approved the first treatment for chronic hepatitis delta virus (HDV) infection, addressing a severe form of viral hepatitis with high mortality.
Alcohol and Sugar: A Dual Metabolic Challenge for Patients
Patients consuming alcohol and high-sugar diets face a compounded metabolic risk, impacting liver function and glucose regulation. Clinicians must address both factors.
Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction
A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Liver Transplant Studies Retracted Over Organ Harvesting Concerns
For atrial fibrillation, integrated pathways may beat individual fixes
The AF-CARE pathway, a comprehensive, integrated management strategy, aims to improve outcomes for atrial fibrillation patients by standardising care.
Smartphones and Pacemakers: Separating Fact from Electromagnetic Fiction
Modern smartphones pose minimal risk of electromagnetic interference with pacemakers and ICDs, provided a safe distance is maintained.
Pulsed Field Ablation: A New Frontier for Atrial Fibrillation?
Pulsed field ablation offers a novel, non-thermal approach to cardiac tissue destruction, leveraging irreversible electroporation for targeted cell death in arrhythmias.
AFib ablation: Stop assuming success based on AFib type alone
Cardiovascular risk: Why men die earlier, women live sicker
Why cardiac amyloidosis diagnoses are surging and what it means for GPs
Tzield expands its reach: A new option for recently diagnosed pediatric type 1 diabetes
The FDA approved Tzield (teplizumab) for pediatric patients with recently diagnosed Stage 3 type 1 diabetes, marking an expansion of its indication.
Pediatric CGM OTC: how will you counsel families?
The FDA has cleared the first over-the-counter continuous glucose monitor for children, expanding access to real-time glucose data for pediatric diabetes management.
Obesity as Disease: Who Benefits from the Redefinition?
Classifying obesity as a disease shifts focus from lifestyle to medical intervention, benefiting pharmaceutical companies and specific patient subgroups.
Targeted Therapy Reverses Weight Gain From Rare Cause of Obesity
Online GLP-1 Prescriptions Often Lack Clinical Oversight
Metabolic Syndrome: Is it accelerating your patients' brain aging?
Football Headers Linked to Cognitive Decline, Neurodegeneration
Repeated head impacts from football headers correlate with increased risk of cognitive impairment and neurodegenerative disease, particularly in former professional players.
Roche Halts Huntington's Gene-Silencing Programs
Roche has ended its gene-silencing programs for Huntington's disease, including tominersen, after clinical trials failed to show benefit or raised safety concerns.
Dopamine Agonists: A Fading Role in Parkinson's Treatment?
Dopamine agonists, once a cornerstone for Parkinson's disease, face increasing scrutiny due to neuropsychiatric side effects and limited long-term motor benefits.
TBI Linked Bidirectionally With Psychiatric and Neurologic Conditions
Cognitive Rehabilitation Eases Long-COVID Brain Fog
Creatine Supplementation: Limited Evidence for Brain Health Benefits
Multiple MyelomaGene therapy for sickle cell: how young is too young for a functional cure?
Get the full story7 min readMAHA Monday: The Rush to Publish and Its Clinical Fallout
Get the full story11 min readLiso-Cel Delivers Durable OS Benefit in R/R LBCL, Redefining Treatment
Get the full story11 min readNew Regimen Confers 'Meaningful' Benefit in Aggressive Lymphoma
Get the full story7 min readFDA Expands Casgevy for Sickle Cell in Children 2 Years and Older
Get the full story8 min readMonoclonal Antibodies May Complicate Transfusion Testing
Get the full story7 min readBlood Transfusion Safety: Pathogen Inactivation Reduces Transfusion-Transmitted Infections
Get the full story7 min readChemo-Free Therapy Improves Outcomes in Pediatric APL (EHA 2026)
Get the full story8 min readPersonalized Hemophilia Care: EHA 2026 Highlights Individualized Approaches
Get the full story7 min readMacrophages: Dual Role in Haematological Malignancies Explored
Get the full story7 min read
Systemic Lupus ErythematosusProstate Care: Balancing Immediate Relief with Long-Term Retreatment
AI in the ED: Can algorithms truly accelerate acute cardiac care?
Haaland's 6,000-Calorie Diet: Performance Fuel or Health Risk?
Eptinezumab Improves Cognitive Symptoms in Migraine Patients
Stopping Spinal Fusion Or Protecting The Gut?
Listen now23 min
Munich, DEAug 28 – 31UpcomingEASD 2026
Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026
Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026
Vienna, ATOct 3 – 7UpcomingAHA 2026
Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026
Stockholm, SEJun 11 – 14PastEULAR 2026
London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30UpcomingESC 2026Munich, DEAug 28 – 31UpcomingEASD 2026Madrid, ESSep 9 – 12UpcomingESMO 2026Berlin, DESep 12 – 16UpcomingERS 2026Copenhagen, DKSep 12 – 15UpcomingECTRIMS 2026Barcelona, ESSep 17 – 20UpcomingUEG Week 2026Vienna, ATOct 3 – 7UpcomingAHA 2026Chicago, USNov 7 – 9UpcomingACR 2026Washington DC, USNov 14 – 19UpcomingASH 2026New Orleans, USDec 12 – 15UpcomingACC.27 Together With WCCHouston, USApr 10 – 12PastENDO 2026Boston, USJun 13 – 16PastEHA 2026Stockholm, SEJun 11 – 14PastEULAR 2026London, GBJun 3 – 6PastASCO 2026Chicago, USMay 29 – Jun 2PastEASL 2026Barcelona, ESMay 27 – 30MunichAug 28 – 31 2026
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
GLP-1 Agonists: Do They Prevent Heart Disease in the General Population?
GLP-1 receptor agonists reduce cardiovascular risk in obese individuals with established CVD, but their benefit in primary prevention remains unclear.
Factor XIa Inhibitors After Heart Attack: A New Antithrombotic Path?
Factor XIa inhibitors offer a novel antithrombotic strategy after myocardial infarction, aiming for reduced bleeding risk compared to current agents.
Eplontersen: Can a new RNAi therapy change ATTR-CM outcomes?
Eplontersen significantly reduced transthyretin protein levels and improved clinical endpoints in ATTR amyloid cardiomyopathy.
Aficamten: A New Path for Non-Obstructive Hypertrophic Cardiomyopathy?
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition with limited treatment options. The drug targets cardiac myosin, reducing contractility and improving symptoms.
Ruling Out Heart Attacks Faster: The PRESC1SE-MI Study's ED Impact
The PRESC1SE-MI study demonstrated a novel algorithm using high-sensitivity troponin I can safely rule out myocardial infarction in the emergency department within one hour.
Do Statins Still Benefit Patients Over 70 Without Prior CVD?
The STAREE trial investigated statin use for primary prevention in individuals over 70, challenging long-held assumptions about cardiovascular benefit in this age group.
Why Transthyretin Amyloid Cardiomyopathy Remains Underdiagnosed
Transthyretin amyloid cardiomyopathy (ATTR-CM) often presents with non-specific symptoms, leading to significant diagnostic delays and missed opportunities for early intervention.
Can Factor XIa Inhibitors Reduce Post-MI Bleeding Without Compromising Efficacy?
Factor XIa inhibitors aim to reduce thrombotic events in acute coronary syndrome patients while minimizing bleeding risk, a critical balance in post-MI care.
Faster Heart Attack Rule-Out: Can PRESC1SE-MI Deliver on ED Efficiency?
A new strategy for ruling out myocardial infarction in emergency departments, using high-sensitivity troponin and clinical risk scores, demonstrated high safety and reduced length of stay.
Do Statins Prevent Dementia in Healthy Older Adults? STAREE Trial Weighs In
The STAREE trial investigated statin use in healthy adults over 70, finding no reduction in dementia incidence but a modest cardiovascular benefit.
Aficamten targets non-obstructive HCM, a disease with no approved drug
Aficamten shows promise for non-obstructive hypertrophic cardiomyopathy, a condition lacking specific approved therapies.
ESC Congress 2026: The 59 Pivotal Trials You Need to Know
Fifty-nine pivotal trials will present at ESC Congress 2026, covering major cardiovascular disease areas from heart failure to arrhythmia.
Lipoprotein(a) Risk: Define, Test Early, Optimise Management
Elevated lipoprotein(a) is an independent, causal risk factor for atherosclerotic cardiovascular disease. Early identification and management are critical.
